You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Johnson and Johnson
Express Scripts
McKinsey
Baxter

Last Updated: May 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,715,724


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,715,724 protect, and when does it expire?

Patent 8,715,724 protects DORYX and DORYX MPC and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,715,724
Title:Tabletting process
Abstract: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.
Inventor(s): Lukas; Stefan (Manningham, AU)
Assignee: Mayne Pharma International Pty Ltd (Melbourne, Victoria, AU)
Application Number:11/666,354
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 8,715,724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-006 Dec 19, 2014 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-001 May 6, 2005 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-004 Apr 11, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-002 May 6, 2005 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-003 Jun 20, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-005 Apr 11, 2013 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,715,724

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2004906219Oct 29, 2004
PCT Information
PCT FiledOctober 28, 2005PCT Application Number:PCT/AU2005/001663
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/045152

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Dow
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.